---
title: "HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL"
id: "nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01197-0"
published_at: "2026-08-07T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01197-0)
- **Published At:** 2026-08-07T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The phase III MATRix/IELSG43 trial provides randomized evidence that **high‑dose myeloablative chemotherapy plus autologous haematopoietic stem‑cell transplantation (HCT–ASCT)** is superior to a non‑myeloablative chemoimmunotherapy consolidation strategy in selected patients with primary central nervous system lymphoma (**PCNSL**). - The trial enrolled 346 **transplant‑eligible**, previously untreated patients with B‑cell PCNSL who began induction therapy with the **MATRix** regimen (high‑dose methotrexate, cytarabine, thiotepa and rituximab). - Of these, 230 patients completed induction and achieved at least a partial response; these patients were randomized 1:1 to consolidation with either **carmustine–thiotepa‑based HCT–ASCT** or two cycles of **R‑DeVIC** (rituximab plus dexamethasone, etoposide, ifosfamide and carboplatin). - The primary end point was **progression‑free survival** measured from time of randomization. - The trial results confirmed the superiority of **HCT–ASCT** over the non‑myeloablative consolidation regimen in this selected, transplant‑eligible population. - Prior to this trial, phase III evidence directly comparing myeloablative HCT–ASCT with non‑myeloablative consolidation in PCNSL had been lacking; MATRix/IELSG43 fills that evidence gap. - The original trial report is published in The Lancet; further methodological and outcome details beyond those summarized in the highlight were not reported in this source. - Clinical implications include supporting **HCT–ASCT** as a standard‑of‑care consolidation option after successful induction with high‑dose methotrexate–based regimens in appropriately selected patients with PCNSL. - The highlight notes selection of patients (transplant‑eligible and who achieved at least a partial response) as important context for interpreting applicability of the results. - For full trial data, outcomes, subgroup analyses and safety details, readers are referred to the original Lancet publication cited in the source.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01197-0#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01197-0) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ About the Editors ](https://www.nature.com/nrclinonc/editors) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [research highlights](https://www.nature.com/nrclinonc/articles?type=research-highlight) 4. article * Research Highlight * Published: 07 August 2026 Haematological cancer # HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL * [David Killock](https://www.nature.com/articles/s41571-026-01197-0#auth-David-Killock-Aff1)[1](https://www.nature.com/articles/s41571-026-01197-0#Aff1) [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01197-0#citeas) [ Save article ](https://www.nature.com/articles/s41571-026-01197-0/save-research?_csrf=2YO5heiR4YC9inwJ_Sp1rHlGrC3Wkt3J) [ View saved research ](https://www.nature.com/saved-research) Standard-of-care consolidation treatment options after high-dose methotrexate-based induction therapy for primary central nervous system lymphoma (PCNSL) include high-dose myeloablative chemotherapy plus autologous haematopoietic stem cell transplantation (HCT–ASCT); however, phase III evidence confirming the benefit of this intensive approach over non-myeloablative consolidation chemoimmunotherapy was lacking. Now, results from the phase III MATRix/IELSG43 trial confirm the superiority of HCT–ASCT in selected patients with PCNSL. In this trial, 346 transplant-eligible patients with previously untreated B cell PCNSL initiated induction treatment comprising four cycles of high-dose methotrexate and cytarabine plus thiotepa and rituximab (MATRix); 230 patients completed induction therapy and had a partial response or better, and they were randomly assigned (1:1) to receive carmustine–thiotepa-based HCT–ASCT or two cycles of rituximab plus dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC). Progression-free survival from the time of randomization was the primary end point. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01197-0) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01197-0) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01197-0) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ## References ### Original article * Illerhaus, G. et al. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. _Lancet_ (2026) [Article](https://doi.org/10.1016%2FS0140-6736%2826%2900917-7) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=42486133) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=High-dose%20chemotherapy%20followed%20by%20autologous%20stem-cell%20transplantation%20versus%20non-myeloablative%20consolidation%20in%20primary%20CNS%20lymphoma%20%28MATRix%2FIELSG43%29%3A%20a%20randomised%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2826%2900917-7&publication_year=2026&author=Illerhaus%2CG) [Download references](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01197-0?format=refman&flavour=references) ## Author information ### Authors and Affiliations 1. Nature Reviews Clinical Oncology David Killock Authors 1. David Killock [View author publications](https://www.nature.com/search?author=David%20Killock) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20Killock)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20Killock%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Corresponding author Correspondence to David Killock. ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=HCT%E2%80%93ASCT%20confirmed%20as%20standard-of-care%20consolidation%20therapy%20for%20PCNSL&author=David%20Killock&contentID=10.1038%2Fs41571-026-01197-0&copyright=Springer%20Nature%20Limited&publication=1759-4774&publicationDate=2026-08-07&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41571-026-01197-0)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41571-026-01197-0) ### Cite this article Killock, D. HCT–ASCT confirmed as standard-of-care consolidation therapy for PCNSL. _Nat Rev Clin Oncol_ (2026). https://doi.org/10.1038/s41571-026-01197-0 [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01197-0?format=refman&flavour=citation) * Published: 07 August 2026 * Version of record: 07 August 2026 * DOI: https://doi.org/10.1038/s41571-026-01197-0 ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative ### Subjects * [B-cell lymphoma](https://www.nature.com/subjects/b-cell-lymphoma) * [Stem-cell therapies](https://www.nature.com/subjects/stem-cell-therapies) * [Cancer therapy](https://www.nature.com/subjects/cancer-therapy) * [CNS cancer](https://www.nature.com/subjects/cns-cancer) * [Randomized controlled trials](https://www.nature.com/subjects/randomized-controlled-trials) [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01197-0) [ Buy or subscribe ](https://www.nature.com/articles/s41571-026-01197-0#access-options) * Sections * References * [References](https://www.nature.com/articles/s41571-026-01197-0#Bib1) * [Author information](https://www.nature.com/articles/s41571-026-01197-0#author-information) * [Rights and permissions](https://www.nature.com/articles/s41571-026-01197-0#rightslink) * [About this article](https://www.nature.com/articles/s41571-026-01197-0#article-info) Advertisement 1. Illerhaus, G. et al. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. _Lancet_ (2026) [Article](https://doi.org/10.1016%2FS0140-6736%2826%2900917-7) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=42486133) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=High-dose%20chemotherapy%20followed%20by%20autologous%20stem-cell%20transplantation%20versus%20non-myeloablative%20consolidation%20in%20primary%20CNS%20lymphoma%20%28MATRix%2FIELSG43%29%3A%20a%20randomised%20phase%203%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2826%2900917-7&publication_year=2026&author=Illerhaus%2CG) Nature Reviews Clinical Oncology (_Nat Rev Clin Oncol_) ISSN 1759-4782 (online) ISSN 1759-4774 (print) ## nature.com footer links ### About Nature Portfolio * [About us](https://www.nature.com/npg_/company_info/index.html) * [Press releases](https://www.nature.com/npg_/press_room/press_releases.html) * [Press office](https://press.nature.com/) * [Contact us](https://support.nature.com/support/home) ### Discover content * [Journals A-Z](https://www.nature.com/siteindex) * [Articles by subject](https://www.nature.com/subjects) * [protocols.io](https://www.protocols.io/) * [Nature Index](https://www.natureindex.com/) ### Publishing policies * [Nature portfolio policies](https://www.nature.com/authors/editorial_policies) * [Open access](https://www.nature.com/nature-research/open-access) ### Author & Researcher services * [Reprints & permissions](https://www.nature.com/reprints) * [Research data](https://www.springernature.com/gp/authors/research-data) * [Language editing](https://authorservices.springernature.com/language-editing/) * [Scientific editing](https://authorservices.springernature.com/scientific-editing/) * [Nature Masterclasses](https://masterclasses.nature.com/) * [Research Solutions](https://solutions.springernature.com/) ### Libraries & institutions * [Librarian service & tools](https://www.springernature.com/gp/librarians/tools-services) * [Librarian portal](https://www.springernature.com/gp/librarians/manage-your-account/librarianportal) * [Open research](https://www.nature.com/openresearch/about-open-access/information-for-institutions) * [Recommend to library](https://www.springernature.com/gp/librarians/recommend-to-your-library) ### Advertising & partnerships * [Advertising](https://partnerships.nature.com/product/digital-advertising/) * [Partnerships & Services](https://partnerships.nature.com/) * [Media kits](https://partnerships.nature.com/media-kits/) * [Branded content](https://partnerships.nature.com/product/branded-content-native-advertising/) ### Professional development * [Nature Awards](https://www.nature.com/immersive/natureawards/index.html) * [Nature Careers](https://www.nature.com/naturecareers/) * [Nature Conferences](https://conferences.nature.com) ### Regional websites * [Nature Africa](https://www.nature.com/natafrica) * [Nature China](http://www.naturechina.com) * [Nature India](https://www.nature.com/nindia) * [Nature Japan](https://www.natureasia.com/ja-jp) * [Nature Middle East](https://www.nature.com/nmiddleeast) * [Privacy Policy](https://www.nature.com/info/privacy) * [Use of cookies](https://www.nature.com/info/cookies) * Your privacy choices/Manage cookies * [Legal notice](https://www.nature.com/info/legal-notice) * [Accessibility statement](https://www.nature.com/info/accessibility-statement) * [Terms & Conditions](https://www.nature.com/info/terms-and-conditions) * [Your US state privacy rights](https://www.springernature.com/ccpa) [ ![Springer Nature](https://www.nature.com/oscar-static/images/logos/sn-logo-white-c8f7a9c061.svg) ](https://www.springernature.com/) © 2026 Springer Nature Limited Close banner Close ![Nature Briefing: Cancer](https://www.nature.com/static/images/logos/nature-briefing-logo-cancer-white-bc2338cade.svg) Sign up for the _Nature Briefing: Cancer_ newsletter — what matters in cancer research, free to your inbox weekly. Email address Sign up I agree my information will be processed in accordance with the _Nature_ and Springer Nature Limited [Privacy Policy](https://www.nature.com/info/privacy). Close banner Close Get what matters in cancer research, free to your inbox weekly. [Sign up for Nature Briefing: Cancer ](https://www.nature.com/briefing/cancer/?brieferEntryPoint=CancerBriefingBanner) *[DOI]: Digital Object Identifier *[ISSN]: International Standard Serial Number
## Related Clinical Research

- [Transjugular Liver Biopsy–Confirmed Lymphoma Presenting as HLH With Severe Thrombocytopenia: Case](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-case-report-transjugular-liver-biopsy-confirmed-lymphoma-presenting-as.md)
- [Low-dose vemurafenib plus rituximab (Scripps regimen) for frontline and relapsed hairy cell leukem](https://medichelpline.com/clinical-feed/pubmed-42308249.md) (DOI: 10.1182/bloodadvances.2025019243)
- [Anti-CD123 CAR-T with Autologous SCT and Venetoclax Maintenance for Refractory BPDCN: Case Report](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-anti-cd123-car-t-therapy-combined-with-autologous-sct-and-venetoclax.md)
- [Nemtabrutinib Plus Venetoclax vs Venetoclax Plus Rituximab in Relapsed/Refractory CLL/SLL](https://medichelpline.com/clinical-feed/clinicaltrials-nct05947851.md) (DOI: NCT05947851)
- [Daratumumab‑VCD for Newly Diagnosed AL Amyloidosis: ANDROMEDA Final Survival Analysis (Blood 2026)](https://medichelpline.com/clinical-feed/pubmed-42118698.md) (DOI: 10.1182/blood.2025032099)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.